Products with Antioxidants bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5931 | Calycosin-7-O-beta-D-glucoside |
| Calycosin-7-O-beta-D-glucoside, a melanin biosynthesis inhibitor, can protect BBB integrity in experimental cerebral ischemia–reperfusion injury via regulating NO/cav-1/MMPs pathway. It attenuates ischemia-reperfusion injuryin vivovia activation of the PI3K/Akt pathway, and has effects on cell apoptosis in cervical cancer HeLa cells and expression of Bcl-2/Bax. | |
| BCN5933 | Phellodendrine |
| Phellodendrine has the effect of suppressing cellular immune response, reducing blood pressure and antinephritis, it also has antioxidant, and anti-inflammatory effects. Phellodendrine can suppress local semisyngeneic GvH reactions and systemic allogeneic GvH reactions in X-ray irradiated recipient mice, it also can suppress the induction phase of sheep red blood cell (SRBC)-induced delayed type hypersensitivity in mice and tuberculin-induced delayed type hypersensitivity in guinea pigs, Phellodendrine can down-regulating AKT, IKK, NF-kB phosphorylation and COX-2 expression induced by AAPH, it also ameliorates the ROS-mediated inflammatory response. | |
| BCN5934 | Phellodendrine chloride |
| 1. Phellodendrine chloride has anti-nephritic activity, may be due to its ability to inhibit the proliferation or the migration of macrophages and cytotoxic T lymphocytes in the glomeruli. | |
| BCN5941 | Glycyrrhizic acid |
| Glycyrrhizic acid has anti-tumor, antiviral ,antiallergic, anti-inflammatory, immunoregulatory,anti-diabetic activities. It is a direct HMGB1(high mobility group box 1) inhibitor that inhibits HMGB1-dependent inflammatory molecule expression and oxidative stress; modulates P38 and P-JNK but not p-ERK signalling; Also inhibits 11 beta-hydroxysteroid dehydrogenase and monoamine oxidase (MAO). | |
| BCN5944 | Liquiritin |
| Liquiritin possesses antidepressant-like, neuroprotective , antioxidant, antiapoptosis, anti-inflammatory and anti-cancer abilities. Liquiritin can attenuate advanced glycation end products-induced endothelial dysfunction via RAGE/NF-κB pathway in human umbilical vein endothelial cells, it may be a promising agent for the treatment of vasculopathy in diabetic patients. | |
